XML 80 R69.htm IDEA: XBRL DOCUMENT
v3.21.2

Segment Reporting - Sales of Company's Products (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020
Segment Reporting Information [Line Items] |  |  |  |
Sales | $ 11,402 | $ 9,353 | $ 22,029 | $ 19,641
Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 11,452 | 9,279 | 22,108 | 19,420
Other |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | (50) | 74 | (79) | 221
United States |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 5,100 | 4,322 | 9,890 | 9,053
United States | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 5,106 | 4,300 | 9,837 | 9,015
United States | Other |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | (6) | 22 | 53 | 38
International |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 6,301 | 5,031 | 12,139 | 10,588
International | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 6,345 | 4,979 | 12,271 | 10,406
International | Other |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | (44) | 52 | (132) | 182
Total Pharmaceutical segment sales | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 9,980 | 8,178 | 19,218 | 17,083
Total Pharmaceutical segment sales | Operating Segments | Keytruda |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 4,176 | 3,388 | 8,076 | 6,672
Total Pharmaceutical segment sales | Operating Segments | Alliance revenue - Lynparza (1) |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 248 | 178 | 475 | 323
Total Pharmaceutical segment sales | Operating Segments | Alliance revenue - Lenvima (1) |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 181 | 151 | 310 | 279
Total Pharmaceutical segment sales | Operating Segments | Gardasil/Gardasil 9 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1,234 | 656 | 2,151 | 1,753
Total Pharmaceutical segment sales | Operating Segments | ProQuad/M-M-R II/Varivax |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 516 | 378 | 965 | 813
Total Pharmaceutical segment sales | Operating Segments | RotaTeq |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 208 | 168 | 366 | 391
Total Pharmaceutical segment sales | Operating Segments | Pneumovax 23 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 152 | 117 | 323 | 373
Total Pharmaceutical segment sales | Operating Segments | Vaqta |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 56 | 28 | 90 | 88
Total Pharmaceutical segment sales | Operating Segments | Bridion |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 387 | 224 | 727 | 524
Total Pharmaceutical segment sales | Operating Segments | Prevymis |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 93 | 63 | 174 | 123
Total Pharmaceutical segment sales | Operating Segments | Noxafil |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 66 | 73 | 133 | 168
Total Pharmaceutical segment sales | Operating Segments | Primaxin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 60 | 64 | 125 | 115
Total Pharmaceutical segment sales | Operating Segments | Cancidas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 54 | 43 | 111 | 98
Total Pharmaceutical segment sales | Operating Segments | Invanz |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 48 | 43 | 104 | 108
Total Pharmaceutical segment sales | Operating Segments | Zerbaxa |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | (1) | 32 | (9) | 69
Total Pharmaceutical segment sales | Operating Segments | Simponi |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 202 | 191 | 416 | 406
Total Pharmaceutical segment sales | Operating Segments | Remicade |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 75 | 73 | 160 | 160
Total Pharmaceutical segment sales | Operating Segments | Belsomra |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 78 | 84 | 157 | 163
Total Pharmaceutical segment sales | Operating Segments | Isentress/Isentress HD |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 192 | 196 | 401 | 441
Total Pharmaceutical segment sales | Operating Segments | Alliance revenue-Adempas/Verquvo (2) |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 74 | 79 | 149 | 133
Total Pharmaceutical segment sales | Operating Segments | Adempas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 74 | 57 | 129 | 113
Total Pharmaceutical segment sales | Operating Segments | Januvia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 784 | 854 | 1,593 | 1,628
Total Pharmaceutical segment sales | Operating Segments | Janumet |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 477 | 490 | 962 | 993
Total Pharmaceutical segment sales | Operating Segments | Other pharmaceutical (3) |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 546 | 548 | 1,130 | 1,149
Total Pharmaceutical segment sales | United States | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 4,647 | 3,958 | 8,941 | 8,266
Total Pharmaceutical segment sales | United States | Operating Segments | Keytruda |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 2,347 | 2,043 | 4,528 | 3,949
Total Pharmaceutical segment sales | United States | Operating Segments | Alliance revenue - Lynparza (1) |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 124 | 105 | 242 | 190
Total Pharmaceutical segment sales | United States | Operating Segments | Alliance revenue - Lenvima (1) |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 88 | 98 | 173 | 188
Total Pharmaceutical segment sales | United States | Operating Segments | Gardasil/Gardasil 9 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 454 | 168 | 766 | 629
Total Pharmaceutical segment sales | United States | Operating Segments | ProQuad/M-M-R II/Varivax |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 386 | 263 | 718 | 596
Total Pharmaceutical segment sales | United States | Operating Segments | RotaTeq |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 111 | 100 | 229 | 241
Total Pharmaceutical segment sales | United States | Operating Segments | Pneumovax 23 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 100 | 21 | 173 | 203
Total Pharmaceutical segment sales | United States | Operating Segments | Vaqta |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 22 | 17 | 47 | 47
Total Pharmaceutical segment sales | United States | Operating Segments | Bridion |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 197 | 107 | 364 | 250
Total Pharmaceutical segment sales | United States | Operating Segments | Prevymis |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 37 | 28 | 72 | 55
Total Pharmaceutical segment sales | United States | Operating Segments | Noxafil |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 14 | 6 | 29 | 14
Total Pharmaceutical segment sales | United States | Operating Segments | Primaxin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 1 | 0 | 1
Total Pharmaceutical segment sales | United States | Operating Segments | Cancidas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1 | (2) | 3 | 1
Total Pharmaceutical segment sales | United States | Operating Segments | Invanz |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | (4) | 0 | 0 | 6
Total Pharmaceutical segment sales | United States | Operating Segments | Zerbaxa |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | (2) | 17 | (4) | 37
Total Pharmaceutical segment sales | United States | Operating Segments | Simponi |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Remicade |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Belsomra |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 14 | 22 | 32 | 49
Total Pharmaceutical segment sales | United States | Operating Segments | Isentress/Isentress HD |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 74 | 76 | 145 | 151
Total Pharmaceutical segment sales | United States | Operating Segments | Alliance revenue-Adempas/Verquvo (2) |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 81 | 73 | 149 | 122
Total Pharmaceutical segment sales | United States | Operating Segments | Adempas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Januvia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 284 | 413 | 632 | 768
Total Pharmaceutical segment sales | United States | Operating Segments | Janumet |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 74 | 143 | 158 | 256
Total Pharmaceutical segment sales | United States | Operating Segments | Other pharmaceutical (3) |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 245 | 259 | 485 | 513
Total Pharmaceutical segment sales | International | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 5,333 | 4,220 | 10,277 | 8,818
Total Pharmaceutical segment sales | International | Operating Segments | Keytruda |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1,829 | 1,345 | 3,548 | 2,722
Total Pharmaceutical segment sales | International | Operating Segments | Alliance revenue - Lynparza (1) |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 124 | 73 | 233 | 133
Total Pharmaceutical segment sales | International | Operating Segments | Alliance revenue - Lenvima (1) |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 93 | 53 | 137 | 91
Total Pharmaceutical segment sales | International | Operating Segments | Gardasil/Gardasil 9 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 781 | 488 | 1,385 | 1,124
Total Pharmaceutical segment sales | International | Operating Segments | ProQuad/M-M-R II/Varivax |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 130 | 115 | 246 | 217
Total Pharmaceutical segment sales | International | Operating Segments | RotaTeq |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 97 | 68 | 137 | 150
Total Pharmaceutical segment sales | International | Operating Segments | Pneumovax 23 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 52 | 96 | 150 | 170
Total Pharmaceutical segment sales | International | Operating Segments | Vaqta |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 34 | 11 | 43 | 41
Total Pharmaceutical segment sales | International | Operating Segments | Bridion |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 190 | 117 | 363 | 274
Total Pharmaceutical segment sales | International | Operating Segments | Prevymis |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 56 | 35 | 103 | 68
Total Pharmaceutical segment sales | International | Operating Segments | Noxafil |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 52 | 67 | 104 | 154
Total Pharmaceutical segment sales | International | Operating Segments | Primaxin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 60 | 63 | 125 | 114
Total Pharmaceutical segment sales | International | Operating Segments | Cancidas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 53 | 45 | 108 | 98
Total Pharmaceutical segment sales | International | Operating Segments | Invanz |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 52 | 43 | 104 | 102
Total Pharmaceutical segment sales | International | Operating Segments | Zerbaxa |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1 | 15 | (5) | 32
Total Pharmaceutical segment sales | International | Operating Segments | Simponi |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 202 | 191 | 416 | 406
Total Pharmaceutical segment sales | International | Operating Segments | Remicade |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 75 | 73 | 160 | 160
Total Pharmaceutical segment sales | International | Operating Segments | Belsomra |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 63 | 61 | 125 | 114
Total Pharmaceutical segment sales | International | Operating Segments | Isentress/Isentress HD |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 118 | 120 | 256 | 290
Total Pharmaceutical segment sales | International | Operating Segments | Alliance revenue-Adempas/Verquvo (2) |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | (7) | 6 | 0 | 11
Total Pharmaceutical segment sales | International | Operating Segments | Adempas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 74 | 57 | 129 | 113
Total Pharmaceutical segment sales | International | Operating Segments | Januvia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 500 | 441 | 961 | 860
Total Pharmaceutical segment sales | International | Operating Segments | Janumet |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 403 | 348 | 805 | 737
Total Pharmaceutical segment sales | International | Operating Segments | Other pharmaceutical (3) |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 301 | 289 | 644 | 637
Total Animal Health segment sales | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1,472 | 1,101 | 2,890 | 2,314
Total Animal Health segment sales | Operating Segments | Livestock |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 821 | 648 | 1,640 | 1,386
Total Animal Health segment sales | Operating Segments | Companion Animals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 651 | 453 | 1,250 | 928
Total Animal Health segment sales | United States | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 459 | 342 | 896 | 726
Total Animal Health segment sales | United States | Operating Segments | Livestock |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 161 | 122 | 318 | 284
Total Animal Health segment sales | United States | Operating Segments | Companion Animals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 298 | 220 | 578 | 442
Total Animal Health segment sales | International | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1,012 | 759 | 1,994 | 1,588
Total Animal Health segment sales | International | Operating Segments | Livestock |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 659 | 526 | 1,322 | 1,102
Total Animal Health segment sales | International | Operating Segments | Companion Animals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 353 | 233 | 672 | 486
Other segment sales (4) | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 23
Other segment sales (4) | United States | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 23
Other segment sales (4) | International | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | $ 0 | $ 0 | $ 0 | $ 0

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=mrk_InternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_KeytrudaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LenvimaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RotateqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_Pneumovax23Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_VaqtaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BridionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_PrevymisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NoxafilMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_PrimaxinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CancidasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_InvanzMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ZerbaxaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_SimponiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BelsomraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_IsentressIsentressHDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AllianceRevenueAdempasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AdempasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanuviaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanumetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LivestockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CompanionAnimalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |